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Abstract
Background: Carbon dioxide (CO2) pneumoperitoneum facilitates the visualization of abdominal organs during
laparoscopic surgery. However, the associated increase in intra-abdominal pressure causes oxidative stress, which
contributes to tissue injury.
Objective: We investigated the ability of the antioxidant and anti-inflammatory drug Erdosteine to prevent CO2
pneumoperitoneum-induced oxidative stress and inflammatory reactions in a rat model.
Methods: Fourteen female adult Wistar albino rats were divided into a control group (Group A, n = 7) and an
Erdosteine group (Group B, n = 7). Group A received 0.5 cc/day 0.9% NaCl, and Group B received 10 mg/kg/day
Erdosteine was administered by gavage, and maintained for 7 days prior to the operation. During the surgical
procedure, the rats were exposed to CO2 pneumoperitoneum with an intra-abdominal pressure of 15 mmHg for
30 min. The peritoneal gas was then desufflated. The rats were sacrificed following 3 h of insufflation. Their lungs
were removed, histologically evaluated, and scored for intra-alveolar hemorrhage, alveolar edema, congestion, and
leukocyte infiltration. The results were statistically analyzed. A value of P < 0.05 was considered statistically
significant.
Results: Significant differences were detected in intra-alveolar hemorrhage (P < 0.05), congestion (P < 0.001), and
leukocyte infiltration (P < 0.001) in Group A compared with Group B. However, the differences in alveolar edema
were not statistically significant (P = 0.698).
Conclusions: CO2 pneumoperitoneum results in oxidative injury to lung tissue, and administration of Erdosteine
reduces the severity of pathological changes. Therefore, Erdosteine may be a useful preventive and therapeutic
agent for CO2 pneumoperitoneum-induced oxidative stress in laparoscopic surgery.
Introduction
Laparoscopic surgical techniques have long been favored in
many therapeutic and diagnostic procedures because they
offer a range of advantages compared with conventional
open techniques. These include less extensive trauma and
discomfort to the patient, decreased duration of hospitali-
zation, minimal wound problems, better cosmetic results,
fewer postoperative pulmonary complications, and shorter
time to recovery [1,2]. This minimally invasive procedure
generally requires a pneumoperitoneum for adequate
visualization and exposure of the structures to be operated
upon. Many gases such as helium, argon, N2O, and CO2
have been used for the creation of pneumoperitoneum.
Currently, CO2 is usually used for insufflation due to
its low cost, nonflammabity, chemical stability, and high
diffusion capacity with subsequent rapid absorption and
excretion [3]. CO2 is also highly soluble and, therefore,
p o s e sal o w e rr i s ko fg a se m b o l i s m .H o w e v e r ,C O 2
pneumoperitoneum also causes an increase in intra-
abdominal pressure above the normal physiological por-
tal circulation pressure (7-10 mmHg), resulting in
splanchnic ischemia. During laparoscopy, there is a
marked reduction in blood flow to the hepatic, renal,
and intestinal circulatory systems. When the laparo-
scopic procedure is completed, abdominal deflation is
performed. This reduces the intra-abdominal pressure
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free oxygen radicals, which are the most important med-
iators of oxidative tissue damage and consequential
organ dysfunction, are generated as a result of ischemia-
reperfusion induced by the inflation and deflation of the
pneumoperitoneum [4]. In general, the most likely
causes of oxidative stress as a consequence of CO2
pneumoperitoneum are ischemia-reperfusion injury due
to changes in the abdominal pressure, inflammation
associated with tissue trauma, and diaphragmatic dys-
function [5]. Oxidative stress damages cellular compo-
nents, causing microvascular leakage and lipid
peroxidation of cellular membranes. This in turn gener-
ates more free radicals, with a self-propagating cycle
leading to pathological changes ranging from edema and
cell injury to cell death by necrosis.
Finally, CO2 pneumoperitoneum can affect several
homeostatic systems, leading to alterations in the acid-
base balance, blood gases, hepatic perfusion, and cardio-
vascular and pulmonary physiology [6]. Frequently,
hypercapnia, acidosis, and systemic and pulmonary
hypertension occur. Organ dysfunction may also occur in
splanchnic organs and even remote organs such as the
lungs. As reported previously, pulmonary complications
of CO2 pneumoperitoneum are represented by hypoxe-
mia, barotrauma, pulmonary edema, and atelectasis [4].
These problems are well tolerated in most patients.
Nevertheless, older patients and those with conditions
such as emphysema and chronic obstructive pulmonary
disease are at risk for depressed pulmonary function and
an increased rate of perioperative complications. Thus,
the reduction or prevention of CO2 pneumoperitoneum-
induced oxidative stress and inflammatory reactions by
antioxidant and anti-inflammatory drugs may be useful
for these patients in clinical practice.
With these issues in mind, we administered prophy-
lactic Erdosteine prior to CO2 pneumoperitoneum in
rats. To our knowledge, this is the first study of this
drug for the treatment of pulmonary complications of
CO2 pneumoperitoneum.
Methods
Population
A prospective, randomized, double-blinded, controlled,
experimental study was conducted with 14 female adult
Wistar albino rats from the same colony weighting 220-
250 g. The rats were obtained from the Experimental
Animals Laboratory of Duzce University Faculty of
Medicine. The purpose of using rats is easy availability,
safety, and the high ratio of repeating the experiment.
Design
The rats were randomly divided into two groups: Group
A: control (n =7 )a n dG r o u pB :E r d o s t e i n e( n =7 ) .
They were maintained under specific pathogen-free con-
ditions to avoid infections and housed separately in a
light-controlled room with a 12:12 h light-dark cycle.
The temperature (22 ± 0.5°C) and relative humidity (65-
70%) were kept constant. Unnecessary stresses were
avoided throughout the study. Standard laboratory
rodent chow and water were available ad libitum. The
animals had not been used in another study or been
given any drugs previously. They were deprived of food
for 12 h before the experiment but had free access to
water.
Group A received 0.5 cc/day 0.9% NaCl, and Group B
received 10 mg/kg/day Erdosteine (Erdostin, Sandoz,
Turkey) was administered by gavage, and maintained for
7 days prior to the operation day. All of the rats were
anesthetized by administering ketamine hydrochloride
(Ketalar, Pfizer, Turkey) 50 mg/kg and xylazine hydro-
chloride (Rompun, Bayer, Turkey) 3 mg/kg intraperito-
neally. During the procedure, additional doses were
administered if necessary. The experiments were per-
formed in a position allowing spontaneous breathing
under sterile conditions. The body temperature was
maintained at 37.0°C with a heat pad to prevent the
effects of hypothermia and to maintain the stability of
hemodynamic parameters.
During the procedure, the animals were placed in a
supine position. A Veress needle was placed supraumbi-
lically into the peritoneal cavity, and a pneumoperito-
neum was established via the insufflation of CO2 by a
CO2 insufflator. The intra-abdominal pressure was set at
15 mmHg. As a result of a decrease in the intra-abdom-
inal pressure due to peritoneal CO2 absorption or CO2
leakage close to the needle, CO2 was automatically
insufflated into the peritoneal cavity to maintain the
intra-abdominal pressure at the desired level. The pneu-
moperitoneum was maintained for 30 minutes, and the
peritoneal gas was then desufflated. The rats were sacri-
ficed by intraperitoneal administration of lethal keta-
mine hydrochloride after 3 hours of insufflation.
The lungs of the rats were removed by median ster-
notomy. The specimens were promptly fixed in 10% for-
malin, dehydrated in graded concentrations of ethanol,
cleared in xylene, and processed for paraffin embedding.
At least six tissue sections 5 μmt h i c kw e r eo b t a i n e d .
Light microscopy was used for histopathological analysis
of the Hematoxylin-Eosin stained sections. One blinded
pathologist analyzed the samples.
Each lung tissue was evaluated for histopathological
changes, including intra-alveolar hemorrhage, alveolar
edema, congestion, and leukocyte infiltration. Intra-
alveolar hemorrhage, alveolar edema, and congestion
were scored on a scale from 0 to 3, where 0 = absence
of pathology (<5% of maximum pathology), 1 = mild
(<10% of maximum pathology), 2 = moderate (15-20%
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maximum pathology) [7]. Leukocyte infiltration was
evaluated to determine the severity of inflammation
resulting from pneumoperitoneum. Each section was
divided into 10 subsections, and leukocyte infiltration
was examined in each of the subsections at a magnifica-
tion of 400× with the following scale: 0, no extravascular
leukocytes; 1, <10 leukocytes; 2, 10-45 leukocytes; 3, >45
leukocytes. An average of the numbers was used for
comparison [7,8].
Ethics
The study was approved by a local ethics board of
Duzce University Faculty of Medicine, Animal Care and
Use Committee in 2009. The rats were cared for in
accordance with the G u i d ef o rt h eC a r ea n dU s eo f
Laboratory Animals.
Statistical analysis
The results were recorded by the principal investigator
and analyzed statistically upon completion of the study.
The statistical analysis was performed with SPSS soft-
ware, version 11.5 (SPSS, Inc., Chicago, IL). Clinical data
were expressed as the median ± the standard error of
mean (minimum-maximum). The parametric Student’s
t-test was used for group comparison, and a P value less
than 0.05 was considered statistically significant.
Results
All 14 rats survived the time to the study start date and
the surgical procedure. Macroscopic examination of the
lungs following removal showed that all specimens were
normal in both groups.
The specimens were histologically evaluated and
scored for intra-alveolar hemorrhage, alveolar edema,
congestion, and leukocyte infiltration. The scores of
intra-alveolar hemorrhage, congestion, and leukocyte
infiltration were lower in Group B than Group A. How-
ever, the scores of alveolar edema in both groups were
similar. All of the scores are presented in Table 1.
Analysis of the specimens from Group A revealed dif-
fuse intra-alveolar hemorrhage. In addition, dense con-
gestion and leukocyte infiltration were present. Slight
alveolar edema was detected around the congestion
areas. Analysis of Group B specimens showed less intra-
alveolar hemorrhage, congestion, and leukocyte infiltra-
tion, especially in alveolar subepithelial regions. Overall,
alveolar edema in this group was almost the same as
Group A. Histopathological photographs of the sections
are shown in Figures 1 &2.
All of the histopathological results were statistically
analyzed for significance. Significant differences were
detected in intra-alveolar hemorrhage (P <0 . 0 5 ) ,c o n g e s -
tion (P < 0.001), and leukocyte infiltration (P < 0.001) in
Group A compared with Group B, with the pathological
changes reduced in the latter group. However, the differ-
ences in alveolar edema were not statistically significant
(P = 0.698) (Table 2).
Discussion
This study of an experimental CO2 pneumoperitoneum
model revealed three points: (a) The predicted antioxi-
dant and anti-inflammatory effects of Erdosteine were
achieved, and histopathological analysis of intra-alveolar
hemorrhage and congestion in the lungs revealed better
results in Group B. (b) Leukocyte infiltration was
reduced in Group B. (c) Erdosteine did not affect the
intensity of alveolar edema in the lungs.
In general, CO2 pneumoperitoneum induces hemody-
namic, pulmonary, renal, splanchnic, and endocrine patho-
physiological changes. In some patients, complications can
develop depending on intra-abdominal pressure, the
amount of CO2 absorbed, the circulatory volume of the
patient, the ventilation technique used, the underlying
pathological conditions, and the type of anesthesia used
[4]. During laparoscopy, an intra-abdominal pressure as
high as 8-20 mmHg is produced and maintained.
Increased intra-abdominal pressure as low as 10 mmHg
causes a considerable decrease in splanchnic blood flow.
The deflation of the pneumoperitoneum reduces the
intra-abdominal pressure and increases splanchnic perfu-
sion, yielding an ischemia-reperfusion model capable of
generating free radicals during the early phase of reperfu-
sion and causing reperfusion injury [9]. It is well known
that ischemia causes considerable tissue damage, which is
exacerbated by reperfusion with oxygenated blood [10].
This ischemia-reperfusion injury is not only limited to
the organs experiencing ischemia-reperfusion but also
Table 1 Histopathological scores of Group A and Group B
Rat No Intra-alveolar
hemorrhage
Alveolar
edema
Congestion Leukocyte
infiltration
Group A-1 10 3 2
Group A-2 11 3 3
Group A-3 10 2 3
Group A-4 10 2 2
Group A-5 11 3 3
Group A-6 11 3 2
Group A-7 11 3 2
Group B-1 00 1 1
Group B-2 00 1 1
Group B-3 10 2 2
Group B-4 01 2 1
Group B-5 12 2 1
Group B-6 10 2 1
Group B-7 10 1 2
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ischemia-reperfusion. As a result of the migration of
inflammatory cells such as macrophages, neutrophils,
and lymphocytes, platelets, fibroblasts, and epithelial
cells join forces to repair the injured tissue. However,
the free oxygen radicals (H2O2,O 2
-,a n dO H
-)a n dp r o -
teases released from the accumulated inflammatory
cells, especially neutrophils can increase the systemic
availability of inflammatory mediators, leading to leuko-
cyte activation and endothelial adhesion molecule
expression and vascular endothelial damage of remote
organs. The free oxygen radicals are capable of reacting
with proteins, nucleic acids, and lipids resulting in lipid
peroxidation of biological membranes [11].
Various organs may control or prevent the damaging
effects of oxidant species by enzymatic and nonenzymatic
antioxidant defense. However, the antioxidant defenses of
the human body are unable to combat fully the effects of
oxidative stress. Therefore, cells contain systems that can
repair deoxyribonucleic acid following attack by radicals,
degrade proteins damaged by radicals, and metabolize
lipid hydroperoxides in membranes [12]. Different strate-
gies such as the establishment of low intra-abdominal
pressure, insufflation with different gases, and drugs that
support the body’s auto defense mechanisms are useful to
prevent CO2 pneumoperitoneum-induced oxidative stress
and inflammatory reactions. Researchers have used various
approaches to prevent this problem. In their experimental
study, Yilmaz et al. compared the levels of free radical pro-
duction and antioxidant status with a pneumoperitoneum
based on helium and CO2, different values of intra-
abdominal pressure. They found that CO2 pneumoperito-
neum produced higher malondialdehyde and carbonyl
responses and resulted in greater sulphydryl consumption
and that helium limited the postoperative oxidative
response following laparoscopy [13]. Uzunkoy et al. admi-
nistered isothermic or hypothermic CO2 pneumoperito-
neum to 30 elective laparoscopic cholecystectomy subjects
Figure 1 Photomicrograph of histopathology from Group A (Control) displaying increased intra-alveolar hemorrhage (thin short
arrow), congestion (thick short arrow), and leukocyte infiltration (thick long arrow). Alveolar edema (double arrow) was slight.
(Hematoxylin-Eosin, original magnification × 20).
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tive period and at 12h following the operation. They con-
cluded that pneumoperitoneum created with isothermic
CO2 resulted in fewer negative effects and rapid post-
operative improvement and suggested that isothermic
CO2 pneumoperitoneum may be preferable in routine
clinical practice for patients with respiratory problems [2].
Nesek-Adam et al. measured several biochemical para-
meters including liver enzymes to determine the effect of
low-pressure pneumoperitoneum and pentoxifylline on
oxidative stress in rabbits. They found that low-pressure
pneumoperitoneum attenuates ischemia-reperfusion injury
and that pretreatment with pentoxifylline does not prevent
the development of oxidative stress [1]. In contrast to
these findings, Dinckan et al. reported in their experimen-
tal study that pentoxifylline could reduce CO2 pneumo-
peritoneum-induced peritoneal oxidative stress [14]. In
addition, Ypsilantis et al. previously demonstrated that
prophylaxis with the antioxidant agent mesna prevented
oxidative stress in the splanchnic organs of rats under-
going CO2 pneumoperitoneum treatment [10].
In our study, we aimed to prevent CO2 pneumoperito-
neum-induced oxidative stress and inflammatory reac-
tions by using Erdosteine, a multifactorial drug with
antibacterial, anti-inflammatory, and antioxidant proper-
ties that can decrease inflammation and oxidative tissue
damage, while taking the physiopathological process of
CO2 pneumoperitoneum into consideration.
Figure 2 Photomicrograph of histopathology from Group B (Erdosteine) displaying decreased intra-alveolar hemorrhage (thin short
arrow), congestion (thick short arrow), and leukocyte infiltration (thick long arrow). Alveolar edema (double arrow) was slight.
(Hematoxylin-Eosin, original magnification × 20).
Table 2 Results of statistical analysis (Median ± SEM)
Parameter Group A Control
(n = 7)
Group B Erdosteine
(n = 7)
Intra-alveolar
hemorrhage
1.00 ± 0.00 0.57 ± 0.53
Alveolar edema 0.57 ± 0.53 0.43 ± 0.79
Congestion 2.71 ± 0.49 1.57 ± 0.53
Leukocyte infiltration 2.43 ± 0.53 1.29 ± 0.49
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its mucolytic and mucokinetic properties. The drug con-
tains two blocked sulfhydryl groups. Following hepatic
metabolization to the active species called Metabolite 1
(Met 1) and opening of the thiolactone ring, one of the
groups contributes to free radical scavenging and anti-
oxidant effects [15,16]. Met 1 has been shown to inhibit
nitric oxide, superoxide, and peroxynitrite production in
vitro during respiratory burst of human neutrophils
[15-17]. The main mechanism of action of Erdosteine
may be related to its ability to inhibit some inflamma-
tory mediators and some proinflammatory cytokines
that are specifically involved in oxidative stress and in
cell membrane damage [17]. Erdosteine prevents the
accumulation of free oxygen radicals when their produc-
tion is accelerated and increases antioxidant cellular
protective mechanisms. In doing so, the drug protects
tissues by reducing lipoperoxidation, elastase activity,
neutrophil infiltration, and cell apoptosis [18,19]. The
efficacy and tolerability of Erdosteine have been demon-
strated over a number of years [19]. Patients may
experience a low incidence of side effects, most of
which are gastrointestinal and generally mild.
We initiated Erdosteine treatment 7 days before the
operation day and maintained the treatment until the
operation day. We selected this 7-day regime because
previous studies have shown that Erdosteine when
administered for 4 days resulted in a substantial decline
in the concentration of both reactive oxygen species and
cytokines in patients with stable chronic obstructive pul-
monary disease. They have also demonstrated a signifi-
cant reduction in the level of 8-isoprostane (a product
of lipid peroxidation) following treatment for 7 days
[20,21]. Several experimental studies have also shown
that Erdosteine at 10 mg/kg/day provides sufficient effi-
cacy [16,18].
Based on histological analyses, we found decreased levels
of intra-alveolar hemorrhage in Group B. In general, CO2
pneumoperitoneum-induced oxidative stress caused
damage to pulmonary tissue and alveolar epithelium cells,
as well as endothelial arteriole and venule cells, leading to
intra-alveolar hemorrhage with disruption of alveoli. The
severity of such intra-alveolar hemorrhage is directly pro-
portional to the level and duration of oxidative stress,
which is the primary cause. During this process, inflamma-
tory cell infiltration in the pulmonary tissue induces the
release of reactive oxygen metabolites, as well as cytokines
and proteolytic-lipolytic enzymes from these cells, after
which these mediators of oxidative stress increase alveolo-
capillary membrane permeability and microvascular leak-
age associated with the formation of intra-alveolar
hemorrhage and alveolar edema fluid. We found that
Erdosteine yielded the expected potent antioxidant effect
and that the level of pulmonary tissue damage was
reduced, which in turn led to a decrease in the level of
intra-alveolar hemorrhage. We also determined that con-
gestion and leukocyte infiltration were significantly
decreased in Group B. Oxidative stress and the accompa-
nying severe inflammation resulted in vasodilatation and
dense congestion as a secondary effect. Erdosteine inhib-
ited the migration of inflammatory cells in Group B to the
area of tissue damage, therefore, suppressing the inflamma-
tion and reducing the severity of congestion. Leukocyte
infiltrations were typically observed 6 to 24 hours after
such operations. Although the rats in our study were sacri-
ficed within 3 hours of administration of CO2 pneumoperi-
toneum and the conclusion of the trial, severe leukocyte
infiltration was detected in the control group. We attribute
this finding to the relatively higher pressure of 15 mmHg
used in CO2 pneumoperitoneum. The duration, however,
is less important than pressure with regards to hemody-
namic effects and complications that may potentially
develop with pneumoperitoneum. The use of a low-pres-
sure pneumoperitoneum may reduce the hazardous effects
of ischemia/insufflation and reperfusion/deflation periods.
Gutt et al. suggested that intra-abdominal pressure main-
tained at moderate to low levels (<12 mmHg) while admin-
istering CO2 pneumoperitoneum can help limit the extent
of the pathophysiological changes and minimize or make
transient any potential organ dysfunction and complica-
tions [4]. Our findings are consistent with those of other
studies. For example, in a study of the effects of Erdosteine
on acute inflammatory changes and fibrosis, Erden et al.
concluded that the drug inhibits acute inflammation by
preventing the migration of neutrophils to the inflamma-
tion site and blocking lipid peroxidation. They noted that
the protective effect of Erdosteine was due to its removal
of free radicals from the environment and its antioxidant
activity [18]. Moretti et al. reviewed acute injury induced
by a variety of pharmacological or noxious agents. They
concluded that Erdosteine prevents the accumulation of
free oxygen radicals when their production is accelerated
and increases antioxidant cellular protective mechanisms,
thereby reducing lipid peroxidation, neutrophil infiltration,
or cell apoptosis mediated by noxious agents [16].
Although the causes of alveolar edema include tissue
inflammation and congestion, we did not detect any signif-
icant alveolar edema in either group during our study. We
are unable to explain fully the pathophysiological and his-
tological basis of this result. However, alveolar edema is a
dynamic phenomenon, and its development is associated
with the disturbance of the balance between the mechan-
isms that force the formation and increase the clearance of
the phenomenon [22]. Therefore, one potential explana-
tion may be that the mechanisms running in contrast with
each other during the trial were all in balance.
Limitations of this experimental study include the low
number of rats, the short postoperative time, and the
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are also based on the result of histopathological exami-
nation. Biochemical data would elucidate physiopatholo-
gical changes associated with CO2 pneumoperitoneum-
induced oxidative damage and the effects of Erdosteine.
Experiments involving a higher number of rats and a
longer postoperative duration may yield more compre-
hensive results. The value of the data obtained in this
study will benefit from future studies that include differ-
ent doses of Erdosteine and time protocols and possibly
different application methods and that biochemically
determine free oxygen radicals, antioxidant enzymes,
and lipid peroxidation products in tissue and blood.
Conclusion
The present study demonstrates that CO2 pneumoperito-
neum results in oxidative stress injury to lung tissue and
that the prophylactic administration of Erdosteine could
reduce the severity of pathological changes in the lungs.
Thus, Erdosteine seems to be a useful preventive and ther-
apeutic agent for CO2 pneumoperitoneum-induced oxida-
tive stress and inflammatory reactions. Although these
findings are not transferrable to clinical practice, they high-
light the future potential of this treatment protocol in
managing pulmonary complications with CO2 pneumoper-
itoneum in laparoscopic surgery. Ultimately, the potential
will depend on the results of clinical Phase 1 and Phase 2
studies of Erdosteine administered to human subjects.
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